{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:50:53Z","timestamp":1793836253775,"version":"4.6.1"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,24]],"date-time":"2018-01-24T00:00:00Z","timestamp":1516752000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","thrombosisresearch.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.thromres.2018.01.039","type":"journal-article","created":{"date-parts":[[2018,2,5]],"date-time":"2018-02-05T22:17:24Z","timestamp":1517869044000},"page":"105-116","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":60,"special_numbering":"C","title":["Endothelial cell functions impaired by interferon in vitro: Insights into the molecular mechanism of thrombotic microangiopathy associated with interferon therapy"],"prefix":"10.1016","volume":"163","author":[{"given":"Haiyan","family":"Jia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Thelwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Dilger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Bird","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Daniels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meenu","family":"Wadhwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2018.01.039_bb0005","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1158\/1541-7786.MCR-14-0450","article-title":"Interferon receptor signaling in malignancy: a network of cellular pathways defining biological outcomes","volume":"12","author":"Fish","year":"2014","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.thromres.2018.01.039_bb0010","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.it.2015.01.002","article-title":"The molecular basis for functional plasticity in type I interferon signaling","volume":"36","author":"Schreiber","year":"2015","journal-title":"Trends Immunol."},{"key":"10.1016\/j.thromres.2018.01.039_bb0015","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.3851\/IMP2306","article-title":"Interferon\u2011\u03b1 for patients with chronic hepatitis delta: a systematic review of randomized clinical trials","volume":"17","author":"Lamers","year":"2012","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.thromres.2018.01.039_bb0020","first-page":"443","article-title":"Interferon\u2011beta\u20111b\u2011induced short- and long-term signatures of treatment activity in multiple sclerosis","volume":"13","author":"Croze","year":"2013","journal-title":"Pharm. J."},{"key":"10.1016\/j.thromres.2018.01.039_bb0025","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s12325-015-0212-6","article-title":"Cumulative review of thrombotic microangiopathy, thrombotic thrombocytopenic purpura, and hemolytic uremic syndrome reports with subcutaneous interferon \u03b2-1a","volume":"32","author":"Ben-Amor","year":"2015","journal-title":"Adv. Ther."},{"key":"10.1016\/j.thromres.2018.01.039_bb0030","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/ajh.2830460220","article-title":"Recombinant interferon alpha and hemolytic uremic syndrome: cause or coincidence?","volume":"46","author":"Harvey","year":"1994","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.thromres.2018.01.039_bb0035","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/ajh.2830470332","article-title":"Hemolytic-uremic syndrome in a patient with chronic myelogenous leukemia treated with interferon alpha","volume":"47","author":"Schlaifer","year":"1994","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.thromres.2018.01.039_bb0040","doi-asserted-by":"crossref","first-page":"723","DOI":"10.2147\/DDDT.S42138","article-title":"Renal thrombotic microangiopathy caused by interferon beta-1a treatment for multiple sclerosis","volume":"7","author":"Mahe","year":"2013","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.thromres.2018.01.039_bb0045","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1056\/NEJMc1316118","article-title":"Thrombotic microangiopathy associated with interferon beta","volume":"370","author":"Hunt","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2018.01.039_bb0050","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1177\/1352458514523692","article-title":"Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in relapsing-remitting multiple sclerosis patients on high-dose interferon \u03b2","volume":"20","author":"Larochelle","year":"2014","journal-title":"Mult. Scler."},{"key":"10.1016\/j.thromres.2018.01.039_bb0055","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2165\/00002018-200124070-00002","article-title":"Drug-induced thrombotic microangiopathy: incidence, prevention and management","volume":"24","author":"Pisoni","year":"2001","journal-title":"Drug Saf."},{"key":"10.1016\/j.thromres.2018.01.039_bb0060","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1056\/NEJMra1312353","article-title":"Syndromes of thrombotic microangiopathy","volume":"371","author":"George","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2018.01.039_bb0065","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","article-title":"VEGF inhibition and renal thrombotic microangiopathy","volume":"358","author":"Eremina","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2018.01.039_bb0070","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1016\/j.humpath.2014.05.015","article-title":"Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature","volume":"45","author":"Usui","year":"2014","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.thromres.2018.01.039_bb0075","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1684\/ecn.2009.0170","article-title":"VEGF-A: a critical regulator of blood vessel growth","volume":"20","author":"Ferrara","year":"2009","journal-title":"Eur. Cytokine Netw."},{"key":"10.1016\/j.thromres.2018.01.039_bb0080","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1006\/bbrc.2001.4761","article-title":"Peptides encoded by exon 6 of VEGF inhibit endothelial cell biological responses and angiogenesis induced by VEGF","volume":"283","author":"Jia","year":"2001","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.thromres.2018.01.039_bb0085","doi-asserted-by":"crossref","first-page":"36148","DOI":"10.1074\/jbc.M401538200","article-title":"Vascular endothelial growth factor (VEGF)-D and VEGF-A differentially regulate KDR-mediated signalling and biological function in vascular endothelial cells","volume":"279","author":"Jia","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.thromres.2018.01.039_bb0090","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.1016\/j.bbagen.2016.08.013","article-title":"A novel role for small molecule glycomimetics in the protection against lipid-induced endothelial dysfunction: involvement of Akt\/eNOS and Nrf2\/ARE signaling","volume":"1861","author":"Mahmoud","year":"2017","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.thromres.2018.01.039_bb0095","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1242\/jcs.048793","article-title":"IP-10 induces dissociation of newly formed blood vessels","volume":"122","author":"Bodnar","year":"2009","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.thromres.2018.01.039_bb0100","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.3892\/ijo.2014.2620","article-title":"Interferon-\u03b2 inhibits glioma angiogenesis through downregulation of vascular endothelial growth factor and upregulation of interferon inducible protein 10","volume":"45","author":"Takano","year":"2014","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.thromres.2018.01.039_bb0105","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/j.1751-7176.2012.00606.x","article-title":"Impaired vasodilation in the pathogenesis of hypertension: focus on nitric oxide, endothelial-derived hyperpolarizing factors, and prostaglandins","volume":"14","author":"Giles","year":"2012","journal-title":"J. Clin. Hypertens. (Greenwich)"},{"key":"10.1016\/j.thromres.2018.01.039_bb0110","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.jmb.2004.05.059","article-title":"Ligand-induced assembling of the type I interferon receptor on supported lipid bilayers","volume":"341","author":"Lamken","year":"2004","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.thromres.2018.01.039_bb0115","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.jmb.2006.11.053","article-title":"Differential receptor subunit affinities of type I interferons govern differential signal activation","volume":"366","author":"Jaks","year":"2007","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.thromres.2018.01.039_bb0120","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1128\/MCB.26.5.1888-1897.2006","article-title":"Inquiring into the differential action of interferons (IFNs): an IFN-alpha2 mutant with enhanced affinity to IFNAR1 is functionally similar to IFN-beta","volume":"26","author":"Jaitin","year":"2006","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.thromres.2018.01.039_bb0125","doi-asserted-by":"crossref","first-page":"32925","DOI":"10.1074\/jbc.M806019200","article-title":"The stability of the ternary interferon-receptor complex rather than the affinity to the individual subunits dictates differential biological activities","volume":"283","author":"Kalie","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.thromres.2018.01.039_bb0130","doi-asserted-by":"crossref","first-page":"ra50","DOI":"10.1126\/scisignal.2004998","article-title":"Multifaceted activities of type I interferon are revealed by a receptor antagonist","volume":"7","author":"Levin","year":"2014","journal-title":"Sci. Signal."},{"key":"10.1016\/j.thromres.2018.01.039_bb0135","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1083\/jcb.201412049","article-title":"Receptor dimerization dynamics as a regulatory valve for plasticity of type I interferon signaling","volume":"209","author":"Wilmes","year":"2015","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.thromres.2018.01.039_bb0140","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/ni.2667","article-title":"Structural basis of a unique interferon-\u03b2 signaling axis mediated via the receptor IFNAR1","volume":"14","author":"de Weerd","year":"2013","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.thromres.2018.01.039_bb0145","first-page":"1253","article-title":"Potentiation of antiglioma effect with combined temozolomide and interferon-beta","volume":"16","author":"Park","year":"2006","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.thromres.2018.01.039_bb0150","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1089\/jir.2009.0103","article-title":"Effects of interferons \u03b1\/\u03b2 on the proliferation of human micro- and macrovascular endothelial cells","volume":"31","author":"Erdmann","year":"2011","journal-title":"J. Interf. Cytokine Res."},{"key":"10.1016\/j.thromres.2018.01.039_bb0155","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1089\/jir.2013.0016","article-title":"The effect of type 1 IFN on human aortic endothelial cell function in vitro: relevance to systemic lupus erythematosus","volume":"34","author":"Reynolds","year":"2014","journal-title":"J. Interf. Cytokine Res."},{"key":"10.1016\/j.thromres.2018.01.039_bb0160","doi-asserted-by":"crossref","first-page":"5373","DOI":"10.4049\/jimmunol.170.11.5373","article-title":"Stimulation of primary human endothelial cell proliferation by IFN","volume":"170","author":"Gomez","year":"2003","journal-title":"J. Immunol."},{"key":"10.1016\/j.thromres.2018.01.039_bb0165","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/1523-1747.ep12514496","article-title":"Effects of rIFN alpha, beta, and gamma on the morphology, proliferation, and cell surface antigen expression of human dermal microvascular endothelial cells in vitro","volume":"95","author":"Ruszczak","year":"1990","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.thromres.2018.01.039_bb0170","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.4049\/jimmunol.181.2.1052","article-title":"IFN-alpha induces transcription of hypoxia-inducible factor-1alpha to inhibit proliferation of human endothelial cells","volume":"181","author":"Gerber","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.thromres.2018.01.039_bb0175","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1186\/1471-2407-9-361","article-title":"Combination of interferon-alpha and 5-fluorouracil inhibits endothelial cell growth directly and by regulation of angiogenic factors released by tumor cells","volume":"9","author":"Wada","year":"2009","journal-title":"BMC Cancer"},{"key":"10.1016\/j.thromres.2018.01.039_bb0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/biores.2014.0052","article-title":"Differential effects of IFN-\u03b2 on the survival and growth of human vascular smooth muscle and endothelial cells","volume":"4","author":"Sano","year":"2015","journal-title":"Biores. Open Access."},{"key":"10.1016\/j.thromres.2018.01.039_bb0185","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/nm0603-653","article-title":"Angiogenesis in health and disease","volume":"9","author":"Carmeliet","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.thromres.2018.01.039_bb0190","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1093\/jnci\/95.6.437","article-title":"Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis","volume":"95","author":"von Marschall","year":"2003","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.thromres.2018.01.039_bb0195","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3109\/08916930903510963","article-title":"Interferon-alpha as angiogenesis inhibitor: learning from tumor models","volume":"43","author":"Indraccolo","year":"2010","journal-title":"Autoimmunity"},{"key":"10.1016\/j.thromres.2018.01.039_bb0200","doi-asserted-by":"crossref","first-page":"H1667","DOI":"10.1152\/ajpheart.00810.2014","article-title":"IFN-\u03b2 affects the angiogenic potential of circulating angiogenic cells by activating calpain 1","volume":"309","author":"Y\u0131ld\u0131r\u0131m","year":"2015","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.thromres.2018.01.039_bb0205","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1023\/A:1026546219962","article-title":"An in vitro model of angiogenesis: basic features","volume":"3","author":"Bishop","year":"1999","journal-title":"Angiogenesis"},{"key":"10.1016\/j.thromres.2018.01.039_bb0210","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.4049\/jimmunol.178.2.1122","article-title":"Identification of genes selectively regulated by IFNs in endothelial cells","volume":"178","author":"Indraccolo","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.thromres.2018.01.039_bb0215","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.4049\/jimmunol.1600108","article-title":"IFN-\u03b1 negatively regulates the expression of endothelial nitric oxide synthase and nitric oxide production: implications for systemic lupus erythematosus","volume":"199","author":"Buie","year":"2017","journal-title":"J. Immunol."},{"key":"10.1016\/j.thromres.2018.01.039_bb0220","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jacc.2013.03.070","article-title":"Effects of nitric oxide on cell proliferation: novel insights","volume":"62","author":"Napoli","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.thromres.2018.01.039_bb0225","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s12872-015-0124-z","article-title":"Endothelial cell control of thrombosis","volume":"15","author":"Yau","year":"2015","journal-title":"BMC Cardiovasc. Disord."},{"key":"10.1016\/j.thromres.2018.01.039_bb0230","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1182\/blood-2016-05-715987","article-title":"Type I interferon causes thrombotic microangiopathy by a dose-dependent toxic effect on the microvasculature","volume":"128","author":"Kavanagh","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2018.01.039_bb0235","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.critrevonc.2017.02.011","article-title":"Interferon induced thrombotic microangiopathy (TMA): analysis and concise review","volume":"112","author":"Kundra","year":"2017","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.thromres.2018.01.039_bb0240","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/jth.13571","article-title":"Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies","volume":"15","author":"Scully","year":"2017","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2018.01.039_bb0245","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1159\/000381515","article-title":"Hypoxia and dysregulated angiogenesis in kidney disease","volume":"1","author":"Tanaka","year":"2015","journal-title":"Kidney Dis. (Basel)"},{"key":"10.1016\/j.thromres.2018.01.039_bb0250","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1073\/pnas.0337679100","article-title":"Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus","volume":"100","author":"Baechler","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.thromres.2018.01.039_bb0255","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1182\/blood-2007-05-089086","article-title":"Interferon-alpha promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis","volume":"110","author":"Denny","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2018.01.039_bb0260","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1002\/art.23035","article-title":"Type I interferon as a novel risk factor for endothelial progenitor cell depletion and endothelial dysfunction in systemic lupus erythematosus","volume":"56","author":"Lee","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.thromres.2018.01.039_bb0265","doi-asserted-by":"crossref","first-page":"4457","DOI":"10.4049\/jimmunol.1001782","article-title":"The detrimental effects of IFN-\u03b1 on vasculogenesis in lupus are mediated by repression of IL-1 pathways: potential role in atherogenesis and renal vascular rarefaction","volume":"185","author":"Thacker","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.thromres.2018.01.039_bb0270","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1136\/annrheumdis-2016-209442","article-title":"Endothelial progenitor dysfunction associates with a type I interferon signature in primary antiphospholipid syndrome","volume":"76","author":"Grenn","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.thromres.2018.01.039_bb0275","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.trsl.2014.10.005","article-title":"Targeting of type I interferon in systemic autoimmune diseases","volume":"165","author":"Crow","year":"2015","journal-title":"Transl. Res."},{"key":"10.1016\/j.thromres.2018.01.039_bb0280","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/art.39962","article-title":"Anifrolumab, an anti-interferon-\u03b1 receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus","volume":"69","author":"Furie","year":"2017","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.thromres.2018.01.039_bb0285","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1089\/hum.2016.023","article-title":"Interferon-inducible Mx promoter-driven, long-term transgene expression system of interferon-\u03b2 for cancer gene therapy","volume":"27","author":"Hamana","year":"2016","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.thromres.2018.01.039_bb0290","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/1878-0261.12020","article-title":"Intracranial AAV-IFN-\u03b2 gene therapy eliminates invasive xenograft glioblastoma and improves survival in orthotopic syngeneic murine model","volume":"11","author":"GuhaSarkar","year":"2017","journal-title":"Mol. Oncol."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384818300471?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384818300471?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T11:10:15Z","timestamp":1603797015000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384818300471"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":58,"alternative-id":["S0049384818300471"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2018.01.039","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Endothelial cell functions impaired by interferon in vitro: Insights into the molecular mechanism of thrombotic microangiopathy associated with interferon therapy","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2018.01.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2018 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}